Autonomix Medical, Inc. (AMIX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Autonomix Medical, Inc. (AMIX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As reported below under Item 5.07 of this Current Report, on October 29, 2026, Autonomix Medical, Inc. (the “Company”) hel
How this was made
The 30-second read
Why it matters
These actions represent a material corporate restructuring for a micro‑cap company, likely influencing share supply and price dynamics.
Market read
The filing introduces new dilution and potential reverse‑split mechanics, which are primary drivers for short‑term price movement in micro‑cap stocks.
What to watch
Potential for the expanded stock plan to incentivize key talent, which may support long‑term growth despite short‑term dilution.
Background
Autonomix Medical, Inc. filed an 8‑K detailing corporate governance changes, including a 750,000‑share increase to its stock plan and a board‑authorized reverse split range of 1‑for‑2 to 1‑for‑25.
Ticker impact
SEC Form 8‑K reports amendments to the 2023 Stock Plan and a proposed reverse stock split, new corporate actions disclosed for the first time.
likely downward pressure as market prices in dilution and reverse‑split uncertainty
First‑time disclosure of share‑increase and reverse‑split authority; micro‑cap stocks typically react negatively to dilution and split uncertainty.
Market effects
Minimal; affects only the niche medical device/diagnostics sector with no broader industry impact.
Limited to U.S. OTC/OTC‑Q market where AMIX trades.
None
Counterpoint
If the reverse split is executed at a favorable ratio, it could improve liquidity and attract institutional interest, offsetting dilution concerns.
Key entities
- companyAutonomix Medical, Inc.
Issuer of the 8‑K filing; subject of the corporate actions.
